Tempest Therapeutics, Inc. (TPST)

NASDAQ: TPST · Real-Time Price · USD

7.00

+0.19 (2.79%)

Jun 4, 2025, 12:31 PM - Market open

Tempest Therapeutics Employees

Tempest Therapeutics had 24 employees as of December 31, 2024. The number of employees increased by 7 or 41.18% compared to the previous year.

Employees

24

Change (1Y)

7

Growth (1Y)

41.18%

Revenue / Employee

n/a

Profits / Employee

-$1,866,625

Market Cap

25.78M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	24	7	41.18%
Dec 31, 2023	17	-2	-10.53%
Dec 31, 2022	19	2	11.76%
Dec 31, 2021	17	3	21.43%
Dec 31, 2020	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

TPST News

21 days ago - Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
5 weeks ago - Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - GlobeNewsWire
6 weeks ago - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - GlobeNewsWire
7 weeks ago - Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value - GlobeNewsWire
2 months ago - Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewsWire
2 months ago - Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
2 months ago - FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
4 months ago - Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma - GlobeNewsWire